Bellevue Group AG / Key word(s): Personnel/AGMEGM Ad hoc announcement pursuant to Art. 53 of the SWX Listing Rules Zurich, February 21, 2023 Changes in the Board of Directors of Bellevue Group Barbara Angehrn Pavik will be proposed for election as a new member of the Board of Directors at the Annual General Meeting of March 21, 2023. Barbara Angehrn Pavik has extensive experience in the healthcare sector that will further strengthen the overall expertise of the Board of Directors. After serving as a director for Bellevue Group for 16 years, Daniel Sigg will not be standing for re-election at the pending Annual General Meeting. Barbara Angehrn Pavik has held a number of executive functions across the international healthcare industry for more than 20 years, most recently as Chief Business Officer and a member of the Executive Board at Vifor Pharma Group. Prior to the four years she spent at Vifor Pharma Group, Barbara Angehrn Pavik was the founder and CEO of Stepstone Pharma and she also held executive positions at Exelixis Pharmaceuticals International, San Francisco, Onyx Pharmaceuticals International, Zug, and Amgen International, Zug. Barbara Angehrn Pavik has been on the Board of Directors of Medmix since 2022. As announced earlier, Bellevue’s long-serving director Daniel Sigg has decided not to stand for re-election at the 2023 Annual General Meeting. Daniel Sigg helped shape Bellevue Group’s strategy for the past 16 years. Veit de Maddalena, Chairman of the Board of Directors, on the Board changes: «We're very pleased that Barbara Angehrn Pavik will serve on Bellevue’s Board of Directors and further strengthen its expertise. With her many years of international experience, she can give our Group, a leading healthcare investment specialist, additional valuable inputs in the years to come. I thank Daniel Sigg for his competent services over the years. He left a distinct mark on Bellevue's corporate development and strategic repositioning. We wish him all the best for the future.»
Financial calendar 2023:
Contact Investor Relations: Michael Hutter, CFO Bellevue Group
Bellevue Additional features: File: Portrait Barbara Angehrn Pavik End of Inside Information |
Language: | English |
Company: | Bellevue Group AG |
Seestrasse 16 | |
8700 Küsnacht | |
Switzerland | |
Phone: | +41 44 267 67 00 |
Fax: | +41 44 267 67 01 |
E-mail: | info@bellevue.ch |
Internet: | www.bellevue.ch |
ISIN: | CH0028422100 |
Valor: | A0LG3Z |
Listed: | SIX Swiss Exchange |
EQS News ID: | 1565157 |
End of Announcement | EQS News Service |
|
1565157 21-Feb-2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.